coronavirus update medicine found

  • 16 min read
  • Jan 10, 2019

Researchers ramp up efforts to develop coronavirus vaccine | News ...
Researchers ramp up efforts to develop coronavirus vaccine | News …

We use it to provide the best experience. If you continue using our website, we will assume that you are happy to receive all cookies on this site

Focus :.

Follow updates coronavirus (Covid-19):

mysterious in Wuhan city of China, now referred to as Covid-19, and spread fast to many other countries, jeopardizing thousands of lives. pandemic vaccine development has been the catalyst of new coronavirus in the biotech industry, both by pharmaceutical companies and research organizations such as the National Institutes of Health (NIH), USA.

The first vaccine Covid-19 in China is expected to be ready for clinical trials by the end of April, according to Xu Nanping, China’s vice minister of science and technology. Inovio Pharmaceuticals plans to begin clinical trials on coronavirus vaccine in April this year.

health officials from WHO has noted that remdesivir Gilead has demonstrated efficacy in treating coronavirus infection.

The National Medical Products Administration of China has approved the use of Favilavir, anti-viral drug, as a treatment for coronavirus. These drugs are reported to have shown success in treating the disease with minimal side effects in a clinical trial involving 70 patients. Clinical trials are underway in Shenzhen, Guangdong province.

Here is a list of coronavirus drug major pharmaceutical companies around the world are developing have the potential to be a great coronavirus vaccines or antivirals to treat infectious coronavirus infection.

Below is a coronavirus vaccines in various stages of development, worldwide.

Medicago is developing drug candidates against COVID-19 after being produced Virus-Like Particle (VLP) of the coronavirus. The company has established a collaboration with Laval University Infectious Disease Research Center to develop antibodies against SARS-CoV-2.

The research activities of the company is partly funded by the Canadian Institutes of Health Research (CIHR).

Airway Therapeutics is exploring novel recombinant human protein called AT-100 (rhSP-D) as a treatment for coronavirus. The company has announced the filing with Respiratory Disease Branch of the National Institutes of Health to evaluate the drug.

AT-100 has shown efficacy in preclinical studies to reduce inflammation and infection in the lungs, while also generating an immune response against a variety of respiratory diseases.

Tiziana Life Sciences is developing a monoclonal antibody named TZLS-501 for the treatment of his COVID 19th. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and the level of IL-6.

elevated drug works by binding IL-6R and depleting the amount of IL-6 circulating in the body, thereby reducing the chronic lung inflammation.

This OyaGen OYA1 has demonstrated antiviral efficacy of the strong against the coronavirus in the laboratory essays. It is found to be more effective than chlorpromazine HCl in inhibiting SARS-CoV-2 self in cell culture.

OYA1 was previously approved as a new drug to treat cancer but was abandoned due to lack of efficacy. OyaGen plan to conduct further studies on the drug to determine efficacy in treating coronavirus.

This BeyondSpring BPI-002 is a small molecule agent indicated to treat a variety of infections including COVID-19. It has the ability to activate CD4 + T helper cells and CD8 + cytotoxic T cells and generate an immune response in the body.

When combined with other vaccines COVID-19, the drug has the ability to generate long-term protection against viral infection. BeyondSpring has filed US patent protection for drugs to treat viral infections.

An intranasal vaccine Covid-19 is being developed by a clinical stage biopharmaceutical company based in the US, Altimmune.

The design and synthesis of single-dose vaccine has been completed, while the animal testing will follow.

coronavirus vaccine is being developed based on a technology platform that is similar to NasoVAX vaccine, influenza vaccine developed by Altimmune.

Inovio Pharmaceuticals has collaborated with Beijing Advaccine Biotechnology Company to advance the development of the former vaccine, INO-4800, as a new coronavirus vaccine. The company has started pre-clinical testing for the manufacture of clinical product,

Vaccine development is supported by $ 9m grant from the Coalition for Innovation Epidemic Preparedness (CEPI).

Inovio announced accelerated time for vaccine development on 03 of March. ongoing preclinical trials and design for human clinical trials have been completed. The company also has set up 3,000 doses for human clinical trials will be conducted throughout the United States, China, and South Korea. Plans for large-scale manufacturing has also been developed.

Human clinical trial in 30 healthy volunteers is expected to begin in April 2020 in the United States, followed by China and South Korea. A phase one clinical trial is planned to be performed in parallel in China, with Beijing Advaccine. Results from clinical trials are expected to be available in September 2020.

Inovio aims to produce one million doses of vaccine by the end of 2020 to conduct additional clinical trials or emergency use.

Algernon Pharmaceuticals has announced that it is exploring its NP-120 (Ifenprodil) as a potential treatment Covid-19. Ifenprodil is N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist is sold under the brand name Cerocal. It has shown its effectiveness in enhancing the survivability of the mice infected with H5N1.

A drug candidate developed by Apeiron Biologics named APN01 being tested in China in the pilot phase of the trial as a treatment for Covid-19. APN01 based on a study conducted by a professor at the University of British Columbia to treat SARS. This study revealed that the ACE2 protein is the primary receptor for the SARS virus.

The clinical trial will test the efficacy of the drug in reducing the viral load in a patient. Data from these trials will be used to determine whether additional clinical trials are required to be carried out in a large number of patients.

Moderna and Vaccine Research Center, a unit of the National Institute of Allergy and Infectious Diseases (NIAID), have collaborated to develop a vaccine for the coronavirus. Goal vaccine Spike (S) protein of coronavirus.

The first bottles of vaccine have been produced in Massachusetts Moderna manufacturing plant and shipped to the NIAID for phase one clinical trial, which is scheduled to begin in April.

Migal Research Institute in Israel announced that the Infectious Bronchitis Virus (IBV) vaccines developed to treat avian coronavirus has been modified to treat Covid-19. The vaccine has shown efficacy in pre-clinical trials conducted by the Volcani Institute.

IBV vaccine was developed after four years of research and has a high genetic similarity to human coronavirus. The institute has been genetically modified vaccine to treat Covid-19 and will be available in oral form.

The institute is currently exploring potential partners to produce vaccine next eight to ten weeks and obtain the necessary approvals for the in-vivo safety testing.

Tonix Pharmaceuticals has partnered with Southern Research, a non-profit research organization, to develop a vaccine coronavirus called TNX-1800. The vaccine was developed using a modified virus horsepox proprietary vaccine platform horsepox this Tonix.

TNX-1800 is designed to express a protein derived from a virus that causes infection of coronavirus. South of research will be responsible for evaluating the effectiveness of vaccines, under the partnership.

Innovation Pharmaceuticals announced that it is evaluating Brilacidin, defensin mimetic drug candidate, as a potential treatment for coronavirus. Brilacidin has demonstrated antibacterial, anti-inflammatory and immunomodulatory in several clinical trials.

The company is planning to explore collaborative research and look for federal grants to develop drugs coronavirus. It is already investigating a drug for inflammatory bowel disease and oral mucositis in cancer patients.

Innovation has signed two material transfer agreement with a university in the United States and 12 in the US biocontainment laboratory for evaluation as a treatment for Covid Brilacidin-19. One biocontainment laboratory is scheduled to commence testing of the drug in the third week of March.

Clover Biopharmaceuticals is developing a recombinant subunit vaccine using trimer-Tag © patented technology. The company is developing vaccines based on trimeric protein S (S-trimer) of Covid 19th coronavirus, which is responsible for bind to host cells and cause infection.

Using a trimer-Tag © technology, Clover managed to produce a subunit vaccine based expression systems, mammalian cell culture on 10 February. The company also identify antigen-specific antibodies in the serum of patients fully recover previously infected by the virus.

A highly purified form of the S-trimer vaccine is expected to be available in six to eight weeks to conduct pre-clinical studies. The company is equipped with in-house cGMP biomanufacturing capability for production scale-up if the vaccine is proven to be successful.

Clover also collaborate with GSK to develop a vaccine adjuvant system uses the last pandemic.

Vaxart is developing a recombinant vaccine orally in tablet formulation using a proprietary platform that its oral vaccine, Vaast.

The company plans to develop a vaccine based on the genome was published from 2019-nCOV be tested in pre-clinical models of mucosal and systemic immune responses.

CytoDyn was checking leronlimab (PRO 140), CCR5 antagonists, as a potential drug coronavirus.

This drug has become studied in phase two clinical trials as a treatment for HIV and has been awarded the status of a fast-track approval by the US Food and Drug Administration.

Child LineaRx Applied DNA Sciences and Takis Biotech form joint ventures in 7 Feb to develop a linear DNA vaccine as a treatment for c oronavirus. The JV will use the Polymerase Chain Reaction (PCR) DNA-based manufacturing technology to develop vaccines.

PCR technology offers several advantages including high purity, increased production speed, and the absence of antibiotics and bacterial contaminants. Furthermore, gene vaccines developed through this technology can be effective without inserted into the genome of the patient.

The design for the four DNA vaccine candidates are expected to be produced using PCR technology to carry out animal testing. Design of a vaccine candidate based on all of the coronavirus spike gene, while the rest is designed based on antigenic portion of the protein.

BIOXYTRAN announced that it is exploring its partners to develop lead drug candidate, BX-25 as a treatment for acute respiratory distress syndrome (ARDS) in patients with end-stage infected with coronavirus. Diffusion of oxygen into the blood consists in patients suffering from ARDS causes the build-up of fluid in the lungs.

BX-25 is designed to be 5,000 times smaller than blood cells and efficient transport of oxygen through the body for a period of nine hours before being processed by the liver. Medication can help in supplying oxygen to vital organs and allows the patient to recover and survive.

Mers Novavax’s vaccine candidate coronavirus

Novavax develops Respiratory Syndrome Novel Middle East (mer) coronavirus vaccine candidate in 2013, posting identification mer coronavirus ((Mers-CoV) in Saudi Arabia in 2012. this is an important target for vaccine development Innovation coronavirus by epidemic Preparedness Coalition (CEPI) and the first priority diseases for the World Health Organization (WHO).

this candidate is designed to primarily bind to the surface of the main S-protein and developed using vaccine technology nanoparticles recombinant company. Tested with adjuvant proprietary Novavax Matrix-M ™, the infection inhibits by inducing an immune response in laboratory studies.

Novavax has received $ 4m in funding from CEPI to advance vaccine development, the company has produced some nanoparticles v accine candidates for testing in animal models and aim to carry out human trials in 2020.

Mers coronavirus associated with severe acute respiratory syndrome (SARS) coronavirus, for companies previously developed a recombinant nanoparticle vaccine candidate.

Inovio Pharma INO-4700

examined DNA immunotherapy, INO-4700 (GLS-5300) is being developed by Inovio in partnership with GeneOne Life Science. It is delivered as an intramuscular vaccine, using a delivery device Cellectra®.

The company has received a $ 5 million grant from the Bill and Melinda Gates Foundation to accelerate the development of Cellectra® delivery devices.

vaccine is well tolerated and showed high immune response against Mers-CoV in 94%patients in early stage clinical trials in July 2019.

It has also generated a broad-based T-cell response in 88% of subjects.

“Research organizations such as the National Institutes of Health (NIH), the US is also developing a vaccine for the coronavirus.”

novel coronavirus drugs in various stages of global development are listed below.

a drug developed by Gilead Sciences ebola were found to be ineffective are now being tested in two Phase III randomized clinical trials in Asian countries.

trials are being conducted on 761 patients in a randomized, placebo-controlled, double-blind study in several hospitals in Wuhan, the center of an outbreak of a new coronavirus. Results from the trial are expected to be available during the next few weeks.

According to a report by The New England Journal of Medicine (NEJM), remdesivir, when administered to patients in the US coronavirus, appear to have been improving the clinical condition.

The University of Nebraska Medical Center is also conducting clinical trials to test the safety and efficacy of the drug. The first patient will be given medication is displaced from the cruise ship Diamond Princess.

China approved the use of Roche Actemra for the treatment of severe complications associated with the coronavirus. Drugs such as Actemra has the ability to prevent the cytokine storm, or an overreaction of the immune system, which is considered as the main reason behind the failure of the organ causes death in some patients coronavirus.

Actemra is also being evaluated in a clinical trial in China, which is expected to enroll 188 patients coronavirus. The clinical trial is expected to be made until May 10.

Galidesivir antiviral drugs (BCX4430) has demonstrated broad-spectrum activity against a variety of pathogens including coronavirus. It is a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication.

The drug has shown a survival benefit in patients against deadly viruses like Ebola, Zika, Marburg and yellow fever.

Galidesivir is currently in the advanced development stage under the Animal Rule to combat a variety of potential virus threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunya virus, and arenaviruses.

Discovered by Regeneron, a combination of a neutralizing monoclonal antibody being studied REGN3048 and REGN3051 against coronavirus infection in a clinical trial the first-in-human, sponsored by the National Institute of Allergy and infectious Diseases (NIAID). Safety and tolerability will be studied in 48 patients.

Both antibodies bind to the S-protein of Mers coronavirus. Intravenous administration of the drug in a mouse model of Mers resulted in a high level of coronavirus neutralization mer in circulating blood with reduced viral load in the lungs.

Regeneron has partnered with Sanofi to be evaluated Kevzara, a fully human monoclonal antibody, in phase two / three clinical trials in patients with COVID-19 infection is severe. Kevzara approved for the treatment of rheumatoid arthritis and is known to block interleukin-6 (IL-6) pathway, which causes an overactive inflammatory response in the lungs Covid-19 patients.

Companies like Inovio Pharmaceuticals, Moderna, and Novavax has reportedly developed a coronavirus vaccine. A total including some traditional medicine for the treatment of coronavirus by Chinese scientists. Chloroquine phosphate has shown efficacy in treating the symptoms of the disease, between 30 therapy. Patients given the drug achieve better reduction in fever and shorter recovery time in a clinical trial conducted in hospitals in Guangdong province and Hunan province.

Enanta Pharmaceuticals has announced plans to develop an antiviral drug candidate for treating COVID-19 patients. The company is testing the compounds of the library there is a potential antiviral compound efficacy in treating COVID-19. It also has launched a drug discovery program to develop a direct-acting drug candidates to treat COVID-19.

Predictive Oncology has launched AI platform for the discovery and development of vaccines against the coronavirus. The company has signed an agreement with InventaBioTech for obtaining soluble Therapeutics, which provides access to technology HSCTM.

will use technology predictive HSCTM together withPredictive modeling platform to deploy AI discovery platform that can filter out the ideal combination of additives and excipients for formulations of proteins.

Emergent Biosolutions is developing two plasma-derived product candidates or hyperimmunes using hyperimmune platform for the treatment of coronavirus. Hyperimmune platform has been used previously for the development of several approved products including vaccines smallpox, botulism, and anthrax.

hyperimmunes is a polyclonal antibody derived from plasma, which is able to generate an immune response and protect against infection. product candidates derived from human plasma named COVID-HIG, while COVID-EIG derived from horse plasma. Both will be explored for the treatment of patients with severe cases of infection.

Integral Molecular has launched a vaccine program using two technology platforms including Shotgun Mutagenesis Epitope Mapping and Membrane Proteome Arrays. Technology will help in understanding the human immune response to coronavirus and isolate the cellular receptors that enable the virus to spread rapidly.

Technology Shotgun help in identifying more than 1,000 binding sites for the antibodies, whereas Membrane Proteome Array technology is able to identify the receptor through which the virus infects a cell.

CEL-SCI is developing immunotherapy against Covid-19 peptides using proprietary LEAPS technology, which utilizes a conserved region of the protein corona to produce T -cell response and reduce viral load. This technology can also be used to develop peptide immunotherapy with both antiviral and anti-inflammatory.

peptides were developed using this technology can help in reducing tissue damage from inflammation caused by infection of the lungs, which is the major cause of death in elderly patients.

AJ vaccine has launched the development of a vaccine against Covid-19. The company will use the latest technology to develop antigens that can mimic the native structure of the virus. This vaccine will be able to stimulate a strong immune response in the body that protect against infection.

Takeda Pharmaceutical Company has announced plans to develop plasma-derived therapies against coronavirus. Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) therapies will be designed to treat high-risk patients. H-IG therapies including antibodies derived from the specific pathogen concentrated plasma of patients cured. These antibodies have the potential to generate an immune response when injected into new patients. plan

Heat Biologics has announced to develop a vaccine for treating or preventing a coronavirus infection using a proprietary platform that its gp96 vaccine. This technology is able to reprogram the living cells to antigen results gp96 proteins that can bind and generate an immune response against the antigen.

Pfizer announced that they had identified the development under certain antiviral compounds that may be effective in treating coronavirus. The company plans to partner with third parties to screen and identify potential compounds in late March and began testing in April.

Mateon Therapeutics has launched a program to develop a treatment antiviral response coronavirus uses his therapy and artificial intelligence (AI) platform. It has also established a division, which will adopt a multi-modal approach to develop treatments Covid-19 as well as other future outbreaks zootonic.

Hong Kong University of Science and Technology has identified several targeted by the vaccine, which can be developed as a treatment for coronavirus. Researchers at the university have identified B cell and T-cell epitopes, which are able to generate an immune response against the SARS virus and the same response to coronavirus.

Some of the epitope identified may be able to generate a specific immune response against Covid-19.

Generex has announced that they are developing a vaccine COVID-19 following a contract from a Chinese consortium comprising China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Development Industry ,

The company will utilize the technology activation of the immune system to produce the Ii-Key peptide Covid-19 to human clinical trials.

Generex will receive an upfront payment of $ 1 million to start the foundation for the development of vaccines and $ 5 million license fee for the technology of its Ii-Key. It is also entitled to receive a 20% royalty on each dose of vaccine produced under contract.

Researchers at Columbia University have been awarded a $ 2.1m grant by Jack Ma Foundation to develop drugs coronavirus. Four different teams at the university will adopt different approaches to the development of a vaccine against the coronavirus.

Tulane University has launched a research program to identify potential drug for coronavirus in the form of a vaccine. The university will use the grant from the Brown Foundation to carry out research activities.

ImmunoPrecise Detection has unveiled a vaccine and therapeutic antibody program to develop vaccines and antibodies against Covid-19. The company will use its B-cells Select ™ and DeepDisplay ™ platform therapeutic compounds against coronavirus invention.

The company has renewed research efforts and noted that it will use the polytope mAb EVQLV TherapyTM and artificial intelligence platform to develop therapies COVID-19.

Serum Institute of India (SII) in collaboration with Codagenix, a US-based biopharmaceutical company, to develop drugs using the coronavirus vaccine strains similar to the original virus. The vaccine is currently in pre-clinical testing stage, while the human trials are expected to commence in the next six months. SII is expected to launch the vaccine in the market at the beginning of 2022.

Southwest Research Institute uses virtual screening called Rhodium to identify potential drug candidates for treating coronavirus of more than two million drug compounds. The most promising compounds will be identified for further development.

Zydus Cadila announced the launch of an accelerated research program to develop a vaccine for Covid-19 uses two new approaches. The first approach involves the development of DNA vaccines against viral membrane protein of the virus, whereas live attenuated vaccine vector recombinant measles virus (RMV) will be developed in the second approach. RMV-based vaccines work by inducing specific neutralizing antibodies, which will provide protection from coronavirus infection.

NanoViricides, a clinical stage company, is working on the development of treatments for nCoV-2019 using its nanoviricide® technology. the company’s technology is used to develop ligands that can bind to the virus in the same way as a cognate receptor and attacked various points viruses.

Vir Biotechnology, a company-stage clinical immunology, announced on 12 February that they had identified two monoclonal antibodies that can bind to the virus that causes Covid-19. Antibodies targeting the spike (S) protein with the virus entering through the cellular receptor ACE2.

The company has formed a partnership with Wuxi Biological on 25 February to commercialize antibodies to treat coronavirus identified. If approved, Wuxi will have the right to market the therapy in China, while Vir will retain the marketing rights in other countries.

Vir has also partnered with Alnylam Pharmaceuticals to identify candidate siRNA targeting the SARS-CoV-2. It has formed another partnership with Biogen to cell line and process development and manufacturing of antibodies.

This Abbvie HIV protease inhibitor, lopinavir being studied together with ritonavir for the treatment mer and SARS coronavirus. Repurposed drug already approved for the treatment of HIV infection with the trade name Kaletra®.

This combination is listed in the WHO list of essential medicines. Lopinavir is believed to act on the intracellular replication of coronaviruses and showed reduced mortality in non-human primates (NHP) model of mer.

lopinavir / ritonavir in combination with ribavirin showed a decrease in the mortality rate and milder course of disease during clinical trials open to patients in the SARS epidemic of 2003.

Cipla also reported its plan to repurpose LOPIMUNE HIV drugs, which is a combination of lopinavir and ritonavir protease inhibitors, for the treatment of coronavirus.

a licensed generic Kaletra®, LOPIMUNE currently available in packs of 60 tablets each, containing 200mg of lopinavir and 50mg of ritonavir.

Janssen Pharmaceutical Companies, a subsidiary ofJohnson & Johnson, donated PREZCOBIX® HIV drugs (darunavir / cobicistat) to be used in research activities aimed at finding a cure for Covid-19.

Darunavir is a protease inhibitor marketed by Janssen. Anecdotal reports indicate darunavir as potential antiviral activity against Covid-19. It is, however, currently approved only for use with the agent to improve, and in combination with other medications for the treatment of HIV-1.

Janssen has no in vitro or clinical data to support the use of darunavir as a treatment for Covid-19. This drug is in the process of being evaluated in vitro for any potential activity against coronavirus.

Furthermore, Janssen has partnered with the Biomedical Advanced Research and Development Authority (Barda) to accelerate the development of Covid- 19 treatment.

infectious coronavirus outbreak in late 2019, the WHO named as Covid-19 (previously 2019-nCoV), led to a medical emergency in the whole world.

similar infections caused by the human alpha and beta like coronavirus 229E, NL63, OC43 and HKU1.

Coronavirus symptoms including those related to the common cold, such as runny nose, headache, cough, fever, and sore throat.

“transmission of coronavirus can occur from person to person or from infected animals such as dogs and cats.”

Covid-19 is betacoronavirus which has its origins bat, according to the Center for Disease Control and Prevention (CDC).

Believed to have been transmitted from animals and reptiles such as snakes, coro naviruses cause respiratory problems such as upper respiratory tract disease and lower respiratory diseases such as pneumonia and bronchitis.

coronavirus transmission can occur from person to person or from infected animals such as dogs and cats.

Move your mouse over the logo to learn more about the companies that made this project possible.

Emisphere Technologies intracellular drug delivery mechanism design unique and sophisticated …

Emisphere Technologies designs unique mechanism of intracellular drug delivery and advanced oral formulations for the pharmaceutical developers.

Follow the company to keep up to date with the company

Emisphere Technologies designs unique mechanism of intracellular drug delivery and advanced oral formulations for the pharmaceutical developers.

Established in 2017, esqLABS provide technology platform, software, consulting, and …

Established in 2017, esqLABS provide technology platform, software, consulting and workshops for data analysis and decision support based model of the entire healthcare industry.

Follow the company to keep up to date with the company

Established in 2017, esqLABS provide a platform technology, software, consulting and workshops for data analysis and decision support based model of the entire industry health.

CSM, Clinigen company, focusing on clinical trial supply and …

CSM, Clinigen company, focuses on the supply of clinical trials and biological sample management services.

Follow the company to keep up to date with the company

CSM, Clinigen company, focuses on the supply of clinical trials and biological sample management services.

Copyright © 2020 Verdict Media Limited.

Go Top

Coronavirus: 11th U.S. Death Recorded Including First In ...
Coronavirus: 11th U.S. Death Recorded Including First In …

Coronavirus treatment and vaccine research races against outbreak ...
Coronavirus treatment and vaccine research races against outbreak …

Coronavirus updates: US states map; 2nd airport screener has virus
Coronavirus updates: US states map; 2nd airport screener has virus

Over 1,700 frontline medics likely infected with coronavirus in ...
Over 1,700 frontline medics likely infected with coronavirus in …

Cases spike outside China, 5 dead in Italy: Virus update
Cases spike outside China, 5 dead in Italy: Virus update

Coronavirus Update: Containment Is Possible, WHO Says : Goats and ...
Coronavirus Update: Containment Is Possible, WHO Says : Goats and …

Coronavirus research suggests epidemic
Coronavirus research suggests epidemic ‘rebound’ in spring …

Coronavirus update: 565 deaths, more than 28,000 cases worldwide ...
Coronavirus update: 565 deaths, more than 28,000 cases worldwide …

These 15 companies are working on coronavirus treatments or ...
These 15 companies are working on coronavirus treatments or …

Unprecedented
Unprecedented’: US prepares for possible coronavirus pandemic as …

Coronavirus updates: 11 test negative in Telangana; results of 7 ...
Coronavirus updates: 11 test negative in Telangana; results of 7 …

Coronavirus updates: Hong Kong reports first coronavirus fatality ...
Coronavirus updates: Hong Kong reports first coronavirus fatality …

More diseases like Wuhan coronavirus will jump from animals to ...
More diseases like Wuhan coronavirus will jump from animals to …

Coronavirus: US to evacuate citizens from quarantined cruise ship ...
Coronavirus: US to evacuate citizens from quarantined cruise ship …

Utter chaos
Utter chaos’: Coronavirus exposes China healthcare weaknesses …

On the genetic and drug trail to contain the deadly coronavirus in ...
On the genetic and drug trail to contain the deadly coronavirus in …

Coronavirus outbreak: doctor in Wuhan hospital dies as army medics ...
Coronavirus outbreak: doctor in Wuhan hospital dies as army medics …

Coronavirus updates: Cases in South Korea surge as U.S. prepares ...
Coronavirus updates: Cases in South Korea surge as U.S. prepares …

Coronavirus update: WHO says window to contain outbreak is ...
Coronavirus update: WHO says window to contain outbreak is …

Coronavirus: Five burning questions scientists want to answer ...
Coronavirus: Five burning questions scientists want to answer …

Germany confirms first human transmission of Wuhan virus in Europe ...
Germany confirms first human transmission of Wuhan virus in Europe …

Hong Kong doctors mull medical strike amid coronavirus outbreak ...
Hong Kong doctors mull medical strike amid coronavirus outbreak …

They Were Infected With the Coronavirus. They Never Showed Signs ...
They Were Infected With the Coronavirus. They Never Showed Signs …

Coronavirus outbreak: Top coronavirus drugs and vaccines in ...
Coronavirus outbreak: Top coronavirus drugs and vaccines in …

What Medications to Get to Prep for a Coronavirus Infection
What Medications to Get to Prep for a Coronavirus Infection

Move to weekly UK coronavirus updates criticised by experts ...
Move to weekly UK coronavirus updates criticised by experts …

Coronavirus death toll in China hits 41 as medical staff struggle ...
Coronavirus death toll in China hits 41 as medical staff struggle …

Coronavirus Research Is Moving at Top Speed—With a Catch | WIRED
Coronavirus Research Is Moving at Top Speed—With a Catch | WIRED

Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say ...
Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say …

Coronavirus in China: The most important lessons from China
Coronavirus in China: The most important lessons from China’s …

Your most pressing questions about the new coronavirus, answered ...
Your most pressing questions about the new coronavirus, answered …

Medical surveillance allowed China to discover novel coronavirus ...
Medical surveillance allowed China to discover novel coronavirus …

Chinese cities try to flush out coronavirus patients by stopping ...
Chinese cities try to flush out coronavirus patients by stopping …

Coronavirus updates in Texas: Dallas, Houston to close bars and ...
Coronavirus updates in Texas: Dallas, Houston to close bars and …

Fact Check: No, India has not developed any treatment for ...
Fact Check: No, India has not developed any treatment for …

Coronavirus: New China figures highlight toll on medical staff - BBC ...
Coronavirus: New China figures highlight toll on medical staff – BBC …

Latest American infected with coronavirus has no relevant travel ...
Latest American infected with coronavirus has no relevant travel …

New developments suggest coronavirus incubation could be longer ...
New developments suggest coronavirus incubation could be longer …

Coronavirus: Largest study suggests elderly and sick are most at ...
Coronavirus: Largest study suggests elderly and sick are most at …

NH Coronavirus Update: Fed Funding Proposed; Tests For 7 Pending ...
NH Coronavirus Update: Fed Funding Proposed; Tests For 7 Pending …

Coronavirus Death Toll Climbs in China, and a Lockdown Widens ...
Coronavirus Death Toll Climbs in China, and a Lockdown Widens …

Coronavirus Treatment Beings Human Trials in China | Time
Coronavirus Treatment Beings Human Trials in China | Time

Key coronavirus question: How are children affected? – Harvard Gazette
Key coronavirus question: How are children affected? – Harvard Gazette

Important Coronavirus Update March 5, 2020 - Oxnard Union High ...
Important Coronavirus Update March 5, 2020 – Oxnard Union High …

Coronavirus outbreak: Artificial intelligence could help find ...
Coronavirus outbreak: Artificial intelligence could help find …

India: Doctor claims to have invented cure for Coronavirus | India ...
India: Doctor claims to have invented cure for Coronavirus | India …

How Doctors Are Treating Patients With Coronavirus Disease : Goats ...
How Doctors Are Treating Patients With Coronavirus Disease : Goats …

Coronavirus: WHO cautions over figures showing slowdown in ...
Coronavirus: WHO cautions over figures showing slowdown in …

Coronavirus: US Impact, China Reopens For Biz | PYMNTS.com
Coronavirus: US Impact, China Reopens For Biz | PYMNTS.com

Coronavirus Update: Employer Response, Contract Performance, and ...
Coronavirus Update: Employer Response, Contract Performance, and …

Countries Struggle to Develop a Vaccine for the New Coronavirus ...
Countries Struggle to Develop a Vaccine for the New Coronavirus …

Cambridge biotech Moderna leads in the race for a coronavirus ...
Cambridge biotech Moderna leads in the race for a coronavirus …

New report on first US case of novel coronavirus details mild ...
New report on first US case of novel coronavirus details mild …

Coronavirus tests U.S. medical system
Coronavirus tests U.S. medical system’s unhealthy reliance on …

Tinggalkan Balasan

Alamat email Anda tidak akan dipublikasikan. Ruas yang wajib ditandai *